局部給藥市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球局部給藥市場價值為 1,563 億美元，預計到 2034 年將以 8.8% 的複合年成長率成長，達到 3,623 億美元。這一成長主要得益於人們對非侵入性治療方法的日益青睞，以及局部和全身性治療中局部用藥產品的廣泛使用。局部給藥依賴於透過皮膚或黏膜給藥活性藥物成分，這是一種方便有效的針對特定區域給藥的方法，無需口服或注射。隨著製劑技術的進步，這些給藥系統現在涵蓋凝膠、噴霧劑、貼片、軟膏和乳霜等各種應用，每種應用都旨在最大限度地提高藥物吸收並增強治療效果。隨著全球醫療保健趨勢轉向家庭自我照護和慢性病管理，對外用解決方案的需求持續激增，尤其是在尋求易於使用和副作用最小的患者群體中。

市場按產品類型細分為液體製劑、半固體製劑、固體製劑及透皮產品。半固體製劑佔最大市場佔有率，佔2024年市場總收入的62.1%。此細分市場包含乳膏、乳液、軟膏、糊劑和凝膠等多個子類別，常用於治療各種皮膚病和發炎。液體製劑（包括混懸液和溶液）以及固體製劑（包括粉劑和栓劑）也越來越受歡迎。同時，透皮產品分為貼片和半固體類型，可提供控釋藥物並增強患者遵從性。

痤瘡、濕疹、牛皮癬和皮膚炎等皮膚相關疾病的普遍存在，促使人們尋求有效的治療方法，尤其是那些易於塗抹且能夠精準緩解症狀的治療方法。隨著這些慢性皮膚問題在全球持續成長，對半固體外用溶液的需求也顯著成長。半固體外用溶液的實用優勢以及快速、局部緩解症狀的能力，使其成為醫護人員和患者的首選。

就給藥途徑而言，2024年，經皮給藥佔市場領先地位，收入佔有率達58.7%。頑固性皮膚病的盛行推動了經皮給藥的應用，這種技術允許患者直接治療患處。由於其操作簡便且能有效控制長期症狀，因此這種方法正日益受到歡迎。患者越來越傾向於自行給藥、無需醫療監督即可在家中輕鬆進行的非手術治療，這有利於進一步擴大市場。

終端用途細分顯示，家庭護理領域創造了最高收入，到2024年將達到669億美元。該領域的成長得益於人們對需要持續管理的慢性疾病便捷治療方案日益成長的需求。局部療法提供了一種比口服或注射藥物更安全、更簡單的替代方案，而口服或注射藥物通常需要專業人士的協助。隨著醫療保健系統持續強調門診護理和居家治療方案，局部給藥系統的使用預計將會擴大。

從地區來看，美國市場表現突出，預計其市場規模將從2023年的591億美元成長至2034年的1,490億美元。強勁成長的動力源於消費者認知度的提升、醫療保健支出的增加以及美國全國範圍內沉重的皮膚病負擔。此外，廣泛的外用產品供應以及對創新藥物輸送技術不斷成長的投資也鞏固了該地區的主導地位。

全球局部給藥領域競爭激烈，跨國公司和小型企業都參與其中。各大公司正加大投資，開發先進的給藥系統，例如微針技術、智慧穿戴裝置和奈米技術驅動的平台。這些創新旨在提高藥效、延長釋放時間並提升患者舒適度。此外，製藥商與醫療研究機構之間的合作正成為加速尖端療法應用策略的關鍵組成部分。監管支持，包括簡化的專利流程和更快的藥品核准，正在進一步鼓勵創新，並加劇這個快速發展的市場的競爭。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 皮膚病和慢性病盛行率上升
    • 配方技術的進步
    • 自我治療的需求不斷成長
  • 產業陷阱與挑戰
    • 皮膚刺激和滲透性有限
    • 監管挑戰
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供應方影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 技術格局
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 - 2034 年

• 主要趨勢
• 半固體製劑
  • 乳霜
  • 軟膏
  • 乳液
  • 凝膠
  • 糊狀物
• 液體製劑
  • 暫停
  • 解決方案
• 固體製劑
  • 粉末
  • 栓劑
• 透皮產品
  • 透皮貼劑
  • 透皮半固體

第6章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 皮膚給藥
• 眼科藥物輸送
• 直腸給藥
• 陰道給藥
• 鼻腔給藥

第7章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 居家照護環境
• 醫院和診所
• 燒傷中心
• 其他最終用途

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Bausch Health Companies
• Bayer
• Cipla
• Eli Lilly and Company
• Galderma Laboratories
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis International
• Pfizer
• Sanofi
• Sun Pharmaceutical Industries
• Taro Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Viatris

The Global Topical Drug Delivery Market was valued at USD 156.3 billion in 2024 and is estimated to grow at a CAGR of 8.8% to reach USD 362.3 billion by 2034. This growth is largely driven by the increasing preference for non-invasive treatment methods and the widespread use of topical products for localized and systemic therapies. Topical drug delivery relies on administering active pharmaceutical ingredients through the skin or mucous membranes, offering a convenient and effective way to target specific areas without the need for oral ingestion or injections. With advancements in formulation technologies, these delivery systems now include a wide variety of applications such as gels, sprays, patches, ointments, and creams, each designed to maximize drug absorption and enhance therapeutic outcomes. As global healthcare trends shift towards self-care and chronic disease management at home, the demand for topical solutions continues to surge, particularly among patients seeking ease of use and minimal side effects.

The market is segmented by product type into liquid formulations, semi-solid formulations, solid formulations, and transdermal products. Semi-solid formulations held the largest market share, accounting for 62.1% of the total market revenue in 2024. This segment includes various subcategories such as creams, lotions, ointments, pastes, and gels, which are commonly used to treat a wide range of skin disorders and inflammatory conditions. Liquid formulations, which include suspensions and solutions, and solid formulations, comprising powders and suppositories, are also gaining traction. Meanwhile, transdermal products are split into patches and semi-solid types, offering controlled drug release and enhanced patient compliance.

The widespread occurrence of skin-related conditions such as acne, eczema, psoriasis, and dermatitis is fueling the need for effective treatment options, particularly those that are easy to apply and deliver targeted relief. As these chronic skin problems continue to rise globally, the demand for semi-solid topical solutions has grown significantly. Their practical benefits and ability to provide quick, localized relief make them a favored choice among both healthcare providers and patients.

In terms of delivery route, dermal drug delivery led the market with a revenue share of 58.7% in 2024. The prevalence of persistent skin conditions has pushed the adoption of dermal applications, which allow patients to treat affected areas directly. This approach is gaining popularity due to its user-friendly nature and effectiveness in managing long-term symptoms. Patients are increasingly leaning toward self-administered, non-surgical treatments that can be easily used in home settings without medical supervision, which supports further market expansion.

End-use segmentation shows that home care settings generated the highest revenue, reaching USD 66.9 billion in 2024. This segment's growth is supported by the rising need for convenient treatment solutions for chronic illnesses that require ongoing management. Topical therapies offer a safer, simpler alternative to oral or injectable medications, which often require professional assistance. As healthcare systems continue to emphasize outpatient care and home-based treatment options, the use of topical drug delivery systems is expected to expand.

Regionally, the U.S. market stood out, with values projected to grow from USD 59.1 billion in 2023 to an estimated USD 149 billion by 2034. This strong growth is fueled by high consumer awareness, increased healthcare spending, and a significant burden of dermatological conditions across the country. The accessibility of a wide range of topical products and growing investment in innovative drug delivery technologies also contribute to the region's dominance.

The global topical drug delivery landscape is highly competitive, with participation from both multinational corporations and smaller firms. Companies are channeling investments into developing advanced delivery systems such as microneedle technologies, smart wearables, and nanotechnology-driven platforms. These innovations aim to improve drug efficacy, extend release profiles, and enhance patient comfort. Additionally, partnerships between pharmaceutical manufacturers and healthcare research institutions are becoming a crucial part of the strategy to accelerate the adoption of cutting-edge therapies. Regulatory support, including simplified patent processes and faster drug approvals, is further encouraging innovation and intensifying competition in this rapidly evolving market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of skin and chronic diseases
    • 3.2.1.2 Advancements in formulation technologies
    • 3.2.1.3 Growing demand for self-administered treatments
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Skin irritation and limited permeability
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Semi-solid formulations
  • 5.2.1 Creams
  • 5.2.2 Ointments
  • 5.2.3 Lotions
  • 5.2.4 Gel
  • 5.2.5 Pastes
• 5.3 Liquid formulations
  • 5.3.1 Suspensions
  • 5.3.2 Solutions
• 5.4 Solid formulations
  • 5.4.1 Powders
  • 5.4.2 Suppositories
• 5.5 Transdermal products
  • 5.5.1 Transdermal patches
  • 5.5.2 Transdermal semi-solids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Dermal drug delivery
• 6.3 Ophthalmic drug delivery
• 6.4 Rectal drug delivery
• 6.5 Vaginal drug delivery
• 6.6 Nasal drug delivery

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Home care settings
• 7.3 Hospitals and clinics
• 7.4 Burn centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Bausch Health Companies
• 9.3 Bayer
• 9.4 Cipla
• 9.5 Eli Lilly and Company
• 9.6 Galderma Laboratories
• 9.7 GlaxoSmithKline
• 9.8 Johnson & Johnson
• 9.9 Merck
• 9.10 Novartis International
• 9.11 Pfizer
• 9.12 Sanofi
• 9.13 Sun Pharmaceutical Industries
• 9.14 Taro Pharmaceutical Industries
• 9.15 Teva Pharmaceutical Industries
• 9.16 Viatris